Cargando…
Anti-PSMA (124)I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle
BACKGROUND: Prostate cancer (PCa) is the second leading cause of cancer-related death in the Western population. The use in oncology of positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent di...
Autores principales: | Frigerio, B., Morlino, S., Luison, E., Seregni, E., Lorenzoni, A., Satta, A., Valdagni, R., Bogni, A., Chiesa, C., Mira, M., Canevari, S., Alessi, A., Figini, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651934/ https://www.ncbi.nlm.nih.gov/pubmed/31337429 http://dx.doi.org/10.1186/s13046-019-1325-6 |
Ejemplares similares
-
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging
por: Frigerio, Barbara, et al.
Publicado: (2016) -
Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review
por: Frigerio, Barbara, et al.
Publicado: (2021) -
Development of (177)Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen
por: Carpanese, Debora, et al.
Publicado: (2020) -
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe
por: Mazzocco, Claire, et al.
Publicado: (2016) -
Co-expression of Skp and FkpA chaperones improves cell viability and alters the global expression of stress response genes during scFvD1.3 production
por: Ow, Dave Siak-Wei, et al.
Publicado: (2010)